CIRS RD Briefing 45: Regulatory timelines in Saudi Arabia
This unique study is the first in-depth analysis of the trends and changes in the regulatory approval times for medicines in the Kingdom of Saudi Arabia. Not only have [...]
CIRS RD Briefing 42: Changing regulatory environment
A summary of the outcome of a survey carried out by the CMR International Institute for Regulatory Science among pharmaceutical companies and regulatory agencies. There was consensus that the [...]
CIRS RD Briefing 41 – Workshop on Regulatory Performance
Highlights from the workshop entitled 'Regulatory Performance: Critical Success Factors in Today’s Environment', held by the CMR International Institute for Regulatory Science in Washington D.C., 15-16 September 2003 In [...]
2004 Workshop report – Development of a model for benefit-risk assessment
Development of a model for benefit-risk assessment of medicines based on multi-criteria decision analysis 29-30th March 2004, London School of Economics (LSE), UK The primary objective of the meeting [...]
CIRS RD Briefing 40 – Pharmacogenetics and pharmacogenomics in drug development
Summarised results of a survey carried out among pharmaceutical companies and regulatory agencies, by the CMR International Institute for Regulatory Science Pharmacogenetic (PGt) and pharmacogenomic (PGx) technologies are being [...]
CIRS RD Briefing 39 – Regulating personalised medicine
Highlights of the workshop "Regulating personalised medicine" organised by the CMR International Institute for Regulatory Science, Nutfield Priory, Surrey, UK, 14-15 April 2003 The unravelling of the human genome [...]
2003 Workshop report – Regulatory performance: Critical success factors
Regulatory performance: Critical success factors in today's environment 15-16th September 2003, Washington DC, USA Participants at the CMR International Institute Workshop on Regulatory Performance found them in the unique [...]
CIRS RD Briefing 38 – Risk management
Highlights of the CMR International institute Workshop on 'Risk Management: Identifying and Developing Effective Stakeholder Communication During Drug Development', held on 12-13 December 2002. Following a number of high [...]
2003 Workshop report – Regulating personalised medicines
Regulating personalised medicines 14-15th April 2003, Surrey, UK The unravelling of the human genome and advances in genetic research are now opening up new horizons in the understanding of [...]
2002 Workshop report – Risk management: Effective stakeholder communication during development
Risk management workshop: Identifying and developing effective stakeholder communication during drug development 12-13th December 2002, Washington DC, USA "Risk is complex and in managing it we must be aware [...]